nabilone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1862 51022-71-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nabilone
  • cesamet
  • LY 109514
  • LY-109514
cannabinol deriv; RN given refers to cpd without isomeric designation; structure
  • Molecular weight: 372.55
  • Formula: C24H36O3
  • CLOGP: 6.72
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.88
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1985 FDA MEDA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
White blood cell count abnormal 345.14 24.41 80 3640 5360 50596044
Gait disturbance 153.05 24.41 109 3611 149896 50451508
Musculoskeletal stiffness 144.15 24.41 99 3621 128382 50473022
Somatic symptom disorder 141.44 24.41 32 3688 1912 50599492
Sacroiliitis 132.22 24.41 32 3688 2565 50598839
Rheumatoid arthritis 126.10 24.41 110 3610 202440 50398964
Insomnia 110.82 24.41 96 3624 174769 50426635
Drug hypersensitivity 93.54 24.41 103 3617 250907 50350497
Therapeutic product effect incomplete 87.35 24.41 64 3656 91451 50509953
Mood altered 85.54 24.41 33 3687 12740 50588664
Therapeutic response shortened 79.10 24.41 27 3693 7362 50594042
Acute psychosis 66.86 24.41 18 3702 2202 50599202
Pain 62.24 24.41 133 3587 578770 50022634
Occult blood 56.97 24.41 14 3706 1193 50600211
Cognitive disorder 54.04 24.41 36 3684 44087 50557317
Dystonia 49.84 24.41 22 3698 11904 50589500
Fibromyalgia 46.35 24.41 33 3687 44945 50556459
Psychotic disorder 42.61 24.41 24 3696 21788 50579616
Mean cell haemoglobin concentration abnormal 35.96 24.41 6 3714 69 50601335
Iron deficiency 35.19 24.41 14 3706 5848 50595556
Dyskinesia 29.98 24.41 21 3699 27840 50573564
Orthostatic hypotension 28.91 24.41 21 3699 29460 50571944
Spinal osteoarthritis 26.15 24.41 15 3705 14077 50587327

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pelvic pain 62.65 38.52 15 1204 2064 29571244
Terminal insomnia 47.51 38.52 9 1210 403 29572905
Immune-mediated hepatitis 45.91 38.52 11 1208 1516 29571792

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Somatic symptom disorder 146.87 24.45 32 4128 1836 64492736
Sacroiliitis 131.65 24.45 32 4128 2980 64491592
Therapeutic product effect incomplete 87.75 24.45 64 4096 103418 64391154
Mood altered 82.54 24.45 33 4127 15946 64478626
Therapeutic response shortened 74.11 24.45 27 4133 10143 64484429
Acute psychosis 59.85 24.45 18 4142 3734 64490838
Fibromyalgia 57.25 24.45 33 4127 35698 64458874
Occult blood 56.71 24.45 14 4146 1388 64493184
Cognitive disorder 53.38 24.45 37 4123 55050 64439522
Dystonia 42.96 24.45 22 4138 18843 64475729
Terminal insomnia 35.85 24.45 9 4151 955 64493617
Immune-mediated hepatitis 35.67 24.45 11 4149 2478 64492094
Psychotic disorder 35.31 24.45 24 4136 34554 64460018
Iron deficiency 34.22 24.45 14 4146 7163 64487409
Blood pressure increased 31.99 24.45 47 4113 172505 64322067
Pelvic pain 31.62 24.45 15 4145 10895 64483677
Mean cell haemoglobin concentration abnormal 27.41 24.45 5 4155 114 64494458
Dyskinesia 25.94 24.45 21 4139 39367 64455205
Musculoskeletal pain 25.91 24.45 29 4131 81265 64413307
Spinal osteoarthritis 24.98 24.45 14 4146 14327 64480245

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A04AD11 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
FDA CS M0003267 Cannabinoids
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175782 Cannabinoid

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Schizophrenia contraindication 58214004 DOID:5419
Hepatic failure contraindication 59927004
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Mania contraindication 231494001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cannabinoid receptor 1 GPCR AGONIST Ki 8.40 CHEMBL CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.20 CHEMBL
Cannabinoid receptor 1 GPCR Ki 8.66 CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.74 CHEMBL

External reference:

IDSource
4019352 VUID
N0000147524 NUI
D05099 KEGG_DRUG
4019352 VANDF
C0068333 UMLSCUI
CHEBI:135574 CHEBI
CHEMBL2218896 ChEMBL_ID
CHEMBL947 ChEMBL_ID
DB00486 DRUGBANK_ID
C011941 MESH_SUPPLEMENTAL_RECORD_UI
5284592 PUBCHEM_CID
9071 IUPHAR_LIGAND_ID
3930 INN_ID
2N4O9L084N UNII
31447 RXNORM
15778 MMSL
38357 MMSL
52672 MMSL
d04587 MMSL
001686 NDDF
322124005 SNOMEDCT_US
395806009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cesamet HUMAN PRESCRIPTION DRUG LABEL 1 0187-1231 CAPSULE 1 mg ORAL NDA 22 sections
Cesamet HUMAN PRESCRIPTION DRUG LABEL 1 0187-1231 CAPSULE 1 mg ORAL NDA 22 sections